Inês Genrinho

Dr. Inês Genrinho

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
PFPedro Lopes Ferreira
Pedro Lopes Ferreira
IGInês Genrinho
Inês Genrinho
TSTânia Santiago
Tânia Santiago
ACAdriana Carones
Adriana Carones
CMCarolina Mazeda
Carolina Mazeda
PMPaulo Monteiro
Paulo Monteiro
(1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese patients with SSc. (2) Methods: A multi-center study was conducted enrolling SSc patients. UCLA GIT 2.0 was validated in Portuguese using reliability (internal consistency, item –total correlation, and reproducibility) and validity (content, construct, and criterion) tests. Criterion tests included EQ-5D and SF-36v2. Social–demographic and clinical data were collected. (3) Results: 102 SSc patients were included, 82.4% of them female, and with a mean sample age of 57.0 ± 12.5 years old. The limited form of SSc was present in 62% of the patients and 56.9% had fewer than five years of disease duration. Almost 60% presented with SSc-GI involvement with a negative impact on quality of life. The means for SF-36v2 were 39.3 ± 10.3 in the physical component summary and 47.5 ± 12.1 in the mental component summary. Total GI score, reported as mild in 57.8% of the patients, was highly reliable (ICC = 0.912) and the Cronbach’s alpha was 0.954. There was a high correlation between the total GI score and EQ-5D-5L and SF-36v2 scores. (4) Conclusion: The Portuguese version of UCLA GIT 2.0 showed good psychometric properties and can be used in research and clinical practice.

1 January 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SASofia Azevedo
Sofia Azevedo
IGInês Genrinho
Inês Genrinho
JSJoana Saldanha
Joana Saldanha
ICInês Cunha
Inês Cunha
Background: Cognitive dysfunction is a frequent but under-recognized feature of fibromyalgia (FM). Its prevalence varies widely across studies, and independent clinical predictors remain uncertain. This study aimed to determine the prevalence of cognitive dysfunction in FM patients compared with healthy controls and identify independent associated factors. Methods: We conducted a case–control study including 47 adult female patients with FM (2016 ACR criteria) and 19 age- and sex-matched healthy controls. Sociodemographic and clinical data were collected. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), with cognitive dysfunction defined as MoCA < 26. Pain (VAS), fatigue (VAS and FACIT-F), anxiety and depression (HADS), sleep quality (PSQI), and disease impact (FIQ-P) were assessed. Univariate analysis was followed by binary logistic regression to identify independent predictors of cognitive dysfunction and multiple linear regression to explore associations with MoCA score. Results: Cognitive dysfunction was present in 72.3% of FM patients versus 5.3% of controls (p < 0.001). FM patients had significantly worse pain scores, fatigue levels, psychological distress, sleep quality, and quality of life (all p < 0.001). In FM patients, MoCA scores correlated inversely with pain (r = −0.34), anxiety (r = −0.34), depression (r = −0.48), disease impact (r = −0.43), and sleep disturbance (r = −0.48), and positively with FACIT-F (r = 0.37) and EQ-5D-5L (ρ = 0.60). In multivariate analysis, higher FIQ-P scores were independently associated with cognitive dysfunction [adjusted OR1.18; 95% CI (1.06–1.30); p < 0.01]. Pain severity [adjusted B = −0.40; 95%CI (−0.64–0.15; p < 0.01)] and depression [adjusted B = −2.60; 95% CI (−4.12–1.04; p = 0.001)] were independently associated with lower MoCA scores. Conclusions: Cognitive dysfunction is highly prevalent in FM and is independently associated with pain severity, depressive symptoms, and disease impact.

4 August 2026 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
IGInês Genrinho
Inês Genrinho
CMCátia Machado
Cátia Machado
AHAlina Humenyuk
Alina Humenyuk
NPNuno Pais
Nuno Pais
ABAnabela Barcelos
Anabela Barcelos

2 November 2025 in Cureus
Verified
Journal Article
Open access
PDF file
IGInês Genrinho
Inês Genrinho
MDMariana Diz-Lopes
Mariana Diz-Lopes
AMAntónio Morais
António Morais
IBIva Brito
Iva Brito
MSMariana Diz-Lopes Sr.
Mariana Diz-Lopes Sr.
Yellow nail syndrome (YNS) is a rare disorder that consists of a clinical triad of thickened yellow nails, lymphedema, and recurring respiratory symptoms. These findings can occur simultaneously or additively, and the characteristic nail changes are an obligatory feature for the diagnosis. The diagnosis of YNS is one of exclusion, and although it is more often an isolated condition, it can occur secondary to immune or neoplastic disorders. Involvement of the respiratory tract occurs in most cases and has a diverse clinical presentation, including pleural effusion and recurrent pneumonia. Due to the rarity of this syndrome and the limited availability of effective treatments, YNS remains associated with substantial morbidity. We present a case of a 58-year-old woman who had a history of recurrent pneumonia, chronic sinusitis, arthralgias, and yellow dystrophic nails that was diagnosed with YNS, and in which daily supplementation with vitamin E resulted in a remarkable clinical improvement.

15 September 2026 in Antibodies
Verified
Journal Article
Open access
PDF file
CMCarolina Mazeda*
Carolina Mazeda*
Eduardo DouradoEduardo Dourado
Eduardo Dourado
RFRaquel Freitas Viterbo Raquel Freitas
Raquel Freitas Viterbo Raquel Freitas
PMPatrícia Martins
Patrícia Martins
LSLILIANA SARAIVA
LILIANA SARAIVA
ICInês Cordeiro
Inês Cordeiro
Background: Autoantibodies are central to the diagnosis and risk stratification of systemic sclerosis (SSc), but their prevalence and clinical associations may vary across populations. This study aimed to evaluate the prevalence and immuno-clinical associations of different autoantibodies in the Rheumatic Diseases Portuguese Register systemic sclerosis cohort. Methods: This was a multicentre observational registry-based study that used data from the Reuma.pt SSc module. Patients were divided according to autoantibody status, and associations between autoantibody expression and clinical data were assessed using appropriate statistical tests, with Bonferroni correction applied for multiple comparisons. Multivariable binary logistic regression was performed for clinically relevant outcomes, with adjustment for sex, age at diagnosis and disease duration. Results: A total of 1080 patients were included, 87.5% female, with a mean age at last evaluation of 60.2 ± 14.6 years and a mean disease duration of 12.4 ± 10.0 years. Limited cutaneous SSc was the most frequent clinical category (57.4%), followed by diffuse cutaneous SSc (17.7%), very early diagnosis of systemic sclerosis (VEDOSS; 12.3%), overlap syndromes (9.8%) and SSc sine scleroderma (2.8%). Antinuclear antibodies were present in 93.4% of patients. Anti-centromere antibodies (ACAs) were the most frequent SSc-specific autoantibodies (54.6%), followed by topoisomerase I antibodies (ATAs; 21.8%). ACA positivity was associated with limited cutaneous disease; older age at diagnosis; and lower frequency of interstitial lung disease (ILD), myositis and flexion contractures. ATA positivity was associated with diffuse cutaneous disease, male sex, higher modified Rodnan skin score (mRSS), digital ulcers, flexion contractures, oesophageal involvement and ILD. Among less frequent autoantibodies, anti-Pm/Scl antibodies were associated with myositis, joint involvement, calcinosis and ILD; anti-U1RNP antibodies with younger age, MCTD overlap, myositis and joint involvement; anti-RNA polymerase III antibodies (ARAs) with scleroderma renal crisis and higher mRSS; anti-U3RNP antibodies with diffuse cutaneous disease and renal involvement; and anti-Ku antibodies with overlap syndromes. Conclusions: In this large real-world SSc cohort, autoantibody status was strongly associated with distinct clinical phenotypes, confirming its value for disease stratification. While most established immuno-clinical associations were reproduced, some differences from international cohorts were observed, supporting the need for population-specific validation of autoantibody associations in SSc.